9 results about "Plasma glucose" patented technology

The invention provides a sugar fat disease death risk prediction method and system based on NHANES data, and the method comprises the steps: obtaining the fasting blood glucose FPG and glycosylated hemoglobin HbA1c clinical detection data of a sugar fat disease patient, and calculating an SHR value through a formula; based on the data of the NHANES database, SHR total cause bilateral critical values of total cause death rate and cardiovascular death rate, SHR cardiovascular bilateral critical values and SHR cancer unilateral critical values of cancer death rate are obtained; and comparing the SHR value with an SHR total cause double-side critical value, an SHR cardiovascular double-side critical value and an SHR cancer single-side critical value of the cancer death rate, and carrying out risk layering and evaluation. The biochemical aging acceleration index has a prediction effect on the diabetes death risk, and KDMAgeAccel significantly intermediates the death risk caused by SHR.

A method for controlling glucose in a flexibly configured dual-hormone artificial pancreas, which manages optional meal and / or exercise notifications using coordinated control actions, comprising the steps of: measuring a plasma glucose signal; calculating the increase (y) of the plasma glucose measurement; defining a model for the increase in plasma glucose; defining carbohydrate intake depending on the carbohydrate content estimated by the patient; and calculating the expected postprandial increase (y) of plasma glucose depending on the administered insulin bolus. * (s) step of defining the increase in corrected plasma glucose TIFF2026529166000143.tif69, corrected insulin infusion volume TIFF2026529166000144.tif59, and adjusted carbohydrate intake Steps to define TIFF2026529166000145.tif69; control action μ r and antagonistic control action μ cr The steps include defining a virtual control action μ(s) divided into and and a nominal value prefilter F r A method comprising the step of calculating a control action using a two-degree-of-freedom (2-DOF) feedback controller having (s).

Provided herein are methods, compounds, and compositions for reducing expression of ApoCIII mRNA and protein in a patient with Fredrickson Type I dyslipidemia, FCS, LPLD. Also provided herein are methods, compounds, and compositions for treating, preventing, delaying, or ameliorating Fredrickson Type I dyslipidemia, FCS, LPLD, in a patient. Further provided herein are methods, compounds, and compositions for increasing HDL levels and / or improving the ratio of TG to HDL and reducing plasma lipids and plasma glucose in a patient with Fredrickson Type I dyslipidemia, FCS, LPLD. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of pancreatitis, cardiovascular disease or metabolic disorder, or a symptom thereof.

A method for improving blood glucose control of a hybrid controller meal and exercise announcement by substituting patient-initiated meal boluses of said hybrid controller by an automatic insulin correction signal without retuning of said hybrid controller, and by incorporating rescue carbohydrates suggestion for hypoglycemia mitigation, comprising the steps of measuring a plasma glucose (G(t)) signal by means of a continuous glucose monitor (CGM), calculating a glucose level (Ĝ(t)) by using a glucose-insulin model; computing a disturbance term d(t), generating a virtual signal uIMC(t), for mitigating the effect of d(t) on the output, by means of an IMC filter Q(s) and converting the virtual signal uIMC(t) into three feed forward actions: insulin infusion, rescue carbohydrate suggestion, and insulin-on-board reduction.

A method for improving blood glucose control of a hybrid controller meal and exercise announcement by substituting patient-initiated meal boluses of said hybrid controller by an automatic insulin correction signal without retuning of said hybrid controller, and by incorporating rescue carbohydrates suggestion for hypoglycemia mitigation, comprising the steps of measuring a plasma glucose (G(t)) signal by means of a continuous glucose monitor (CGM), calculating a glucose level (Ĝ(t)) by using a glucose-insulin model; computing a disturbance term d(t), generating a virtual signal uIMC(t), for mitigating the effect of d(t) on the output, by means of an IMC filter Q(s) and converting the virtual signal uIMC(t) into three feed forward actions: insulin infusion, rescue carbohydrate suggestion, and insulin-on-board reduction.

The present invention relates to a method of controlling glucose in a flexible structure dual hormone artificial pancreas, the method managing optional meal and / or exercise alerts by means of coordinated control behavior, the method comprising: measuring a plasma glucose signal; calculating an incremental plasma glucose measure (y); defining an incremental plasma glucose model; defining carbohydrate uptake as a carbohydrate content estimated depending on the patient; defining an expected postprandial incremental plasma glucose according to the administered insulin bolus; defining a corrected incremental plasma glucose, a corrected insulin infusion, and a corrected carbohydrate uptake; defining a virtual control behavior, which is allocated between a regulatory behavior and an anti-regulatory behavior; and calculating the control behavior with a 2-DOF feedback controller having a pre-filter having a nominal value s).

The invention relates to a method for controlling glucose in a flexible-structure bihormonal artificial pancreas that manages optional meal and / or exercise alerts by means of coordinated control actions, comprising: measuring a plasma glucose signal; calculating an incremental plasma glucose measurement (y); defining a model for incremental plasma glucose; defining a carbohydrate ingestion as dependent on a carbohydrate content estimated by the patient; defining an expected postprandial incremental plasma glucose y*(s) according to an insulin bolus that has been administered; defining a corrected incremental plasma glucose y̅(s), a corrected insulin infusion ū(s) and a corrected carbohydrate ingestion d̅(s); defining a virtual control action μ(s), divided between regulatory actions μ r and counterregulatory actions μ cr ; and calculating the control actions using a 2-DOF feedback controller with a prefilter having a nominal value F r (s).

A method for controlling glucose in a flexibly structured dual-hormone artificial pancreas that manages optional meal and / or exercise notifications using coordinated control actions, which comprises: measuring a plasma glucose signal; calculating an incremental plasma glucose measurement (y); defining a model for incremental plasma glucose; defining a carbohydrate intake as dependent on a carbohydrate content estimated by the patient; defining an expected postprandial incremental plasma glucose y*(s) depending on the insulin bolus administered; defining a corrected incremental plasma glucose y(s), a corrected insulin infusion u(s), and a corrected carbohydrate d(s) intake; defining a virtual control action µ(s), divided into regulatory actions µr and counter-regulatory actions µcr and calculating control actions using a 2-DOF feedback controller with a nominal value pre-filter Fr(s).

The present invention discloses a data processing device for individualized prediction and calibration of glycated hemoglobin values ​​and auxiliary judgment of the risk of elevated blood sugar. It includes the following modules: (A) a data receiving module, the data receiving module is configured to receive at least one of the following parameters: a single fasting plasma blood sugar, a single 2-hour postprandial plasma blood sugar, the arithmetic mean of multiple fasting capillary blood sugars, the calculated arithmetic mean of multiple 2-hour postprandial capillary blood sugars, and a single glycated albumin; (B) a data calculation module; the data calculation module is configured to receive data from the data receiving module; the data calculation module includes a parameter calculation module 1 and a parameter calculation module 2, which calculates and obtains the HbA1c point estimate; the HbA1c prediction range width and the HbA1c point estimate are set according to clinical needs, and the lower limit and upper limit of the HbA1c prediction range of the subject to be tested are calculated. The present invention adopts a method of setting the prediction range width according to clinical needs, which improves the accuracy of auxiliary judgment of elevated blood sugar.